Talquetamab in relapsed refractory multiple myeloma: multi-institutional real-world study.

Area of Science:

• Oncology
• Immunotherapy
• Hematology

Background:

• Talquetamab is a GPRC5DxCD3 bispecific antibody for relapsed/refractory multiple myeloma (RRMM).
• RRMM patients often have limited treatment options, especially after multiple prior therapies.

Purpose of the Study:

• To evaluate the real-world efficacy and safety of talquetamab in heavily pretreated RRMM patients.
• To assess response rates, survival outcomes, and adverse events associated with talquetamab treatment.

Main Methods:

• Multicenter retrospective analysis of 114 RRMM patients treated with talquetamab.
• Data collected on patient characteristics, prior therapies, treatment response, survival, and adverse events.

Main Results:

• Overall response rate (ORR) was 73%, with 26% complete response (CR).
• Median progression-free survival (PFS) was 10 months; 6-month PFS and overall survival (OS) rates were 56% and 86%.
• Common adverse events included cytokine release syndrome (CRS; 54%), infections (27%), and neurotoxicity (9.8%); significant weight loss was also observed.

Conclusions:

• Talquetamab demonstrates significant efficacy in a heavily pretreated RRMM population.
• Management of toxicities, including infections and weight loss, is crucial for optimal patient care.